Eli Lilly and Company
LLY
$732.41
$11.501.60%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 45.04B | 40.86B | 38.92B | 35.93B | 34.12B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.04B | 40.86B | 38.92B | 35.93B | 34.12B |
| Cost of Revenue | 8.42B | 7.80B | 7.49B | 7.13B | 7.08B |
| Gross Profit | 36.62B | 33.06B | 31.43B | 28.80B | 27.04B |
| SG&A Expenses | 8.13B | 7.63B | 7.34B | 7.14B | 6.94B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.54B | 25.97B | 25.03B | 24.12B | 23.34B |
| Operating Income | 17.50B | 14.90B | 13.89B | 11.81B | 10.79B |
| Income Before Tax | 12.68B | 10.15B | 8.99B | 7.56B | 6.55B |
| Income Tax Expenses | 2.09B | 1.78B | 1.65B | 1.42B | 1.31B |
| Earnings from Continuing Operations | 10.59K | 8.37K | 7.34K | 6.14K | 5.24K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.59B | 8.37B | 7.34B | 6.14B | 5.24B |
| EBIT | 17.50B | 14.90B | 13.89B | 11.81B | 10.79B |
| EBITDA | 19.27B | 16.57B | 15.50B | 13.37B | 12.31B |
| EPS Basic | 11.74 | 9.28 | 8.14 | 6.81 | 5.81 |
| Normalized Basic EPS | 11.69 | 9.95 | 9.32 | 7.92 | 7.24 |
| EPS Diluted | 11.71 | 9.25 | 8.12 | 6.79 | 5.80 |
| Normalized Diluted EPS | 11.66 | 9.92 | 9.30 | 7.91 | 7.23 |
| Average Basic Shares Outstanding | 3.61B | 3.61B | 3.61B | 3.60B | 3.60B |
| Average Diluted Shares Outstanding | 3.62B | 3.62B | 3.61B | 3.61B | 3.61B |
| Dividend Per Share | 5.20 | 5.03 | 4.86 | 4.69 | 4.52 |
| Payout Ratio | 44.20% | 54.12% | 59.60% | 68.77% | 77.65% |
